Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Consult board-certified experts
A medication being codeveloped by Boehringer Ingelheim and Zealand Pharma is survodutide, which combines a GLP-1 agonist and glucagon
Rare but serious adverse effects include pancreatitis (though causality remains uncertain), gallbladder disease, and potential thyroid C-cell tumors (observed in rodent studies but not conclusively demonstrated in humans)
Our medical team monitors your progress and adjusts your treatment plan to ensure optimal results throughout your weight loss journey
US$ 26.99
US$ 26.15
US$ 20.56
US$ 23.33
